Citable segment mix
DGX's latest SEC segment disclosure for revenue by product shows Routine clinical testing and other services as the largest listed segment at $1 (51.0% of disclosed segment revenue).
| Segment | Period | Revenue | Mix |
|---|---|---|---|
| Routine clinical testing and other services | Sep 30, 2023 | $1 | 51.0% |
| Gene-based and esoteric (including advanced diagnostics) testing services | Sep 30, 2023 | $0 | 39.0% |
| Anatomic pathology testing services | Sep 30, 2023 | $0 | 6.0% |
| All other services | Sep 30, 2023 | $0 | 3.0% |
| COVID-19 testing services | Sep 30, 2023 | $0 | 1.0% |
Source: SEC EDGAR segment disclosures; period Sep 30, 2023.
Continue research
Follow same-sector companies and source explainers connected to the segments view.
A factual guide to revenue segment disclosures and how Aerarium Research uses them to make company business mix easier to inspect.
A factual guide to seasonal revenue patterns and comparable (same-store) sales — why year-over-year comparisons matter and what comp sales strip out.
A factual guide to deferred revenue, cash collected before revenue is earned, and why the liability can matter for recurring businesses.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
